AbbVie’s Humira Replacement Strategy Is Working—But the Next Patent Cliff Starts Now
Skyrizi and Rinvoq have replaced Humira’s growth engine. Now AbbVie must prove that its acquisition-led pipeline can outrun the next patent cliff.
Read the story
Language
Search languages…
No languages found
104 languages available
No languages found
104 languages available
Skyrizi and Rinvoq have replaced Humira’s growth engine. Now AbbVie must prove that its acquisition-led pipeline can outrun the next patent cliff.
Read the story
Novartis del desiran impairment reveals how a trial miss reduced acquired research value, stranded manufacturing capacity and tested capital allocation.
Read the story
Novartis is paying $575 million upfront for Abogen’s mRNA platform while keeping most of a $7.8 billion headline contingent. The real test is disciplined…
Read the story
Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestones. The structure turns litigation into a staged immunology option—and makes…
Read the story